Comparison of 2.5 mg/kg and 5 mg/kg systemic bevacizumab in neovascular age-related macular degeneration: twenty-four week results of an uncontrolled, prospective cohort study.

Background: To compare safety, visual acuity (VA), and anatomic outcomes of 2.5 mg/kg and 5 mg/kg intravenous bevacizumab in patients with neovascular age-related macular degeneration.

Methods: In an institutional cohort study, 16 patients (2 cohorts, 27 eyes) with neovascular age-related macular degeneration were treated with 5 mg/kg intravenous bevacizumab and 2.

Same-day administration of verteporfin and ranibizumab 0.5 mg in patients with choroidal neovascularisation due to age-related macular degeneration.

Objective: To evaluate safety of same-day administration of verteporfin and ranibizumab.

Methods: Prospective, open-label, multicentre study; patients with predominantly classic (n = 13) or occult (n = 19) choroidal neovascularisation secondary to age-related macular degeneration received standard-fluence verteporfin at baseline and months 3, 6 and 9, based on fluorescein angiography (FA). Ranibizumab 0.

Management of extensive subfoveal haemorrhage secondary to neovascular age-related macular degeneration.

Background: To evaluate the clinical outcomes of subfoveal haemorrhages secondary to neovascular age-related macular degeneration (AMD), which were treated with intravitreal recombinant tissue plasminogen activator (rTPA)/gas and anti-vascular endothelial growth factor (anti-VEGF) drug or with an intravitreal anti-VEGF monotherapy.

Methods: This is a retrospective pilot study. Patients who received intravitreal rTPA/gas and anti-VEGF injections (n=20, bevacizumab or ranibizumab) were included in group A.

Time course of morphologic effects on different retinal compartments after ranibizumab therapy in age-related macular degeneration.

Purpose: To analyze the effect of ranibizumab therapy on retinal and subretinal compartments in age-related macular degeneration and to compare the time course of compartment specific effects to visual function.

Design: Prospective noncomparative case series.

Participants: Fourteen patients with changes in 3 major compartments owing to neovascular age-related macular degeneration.

Interexaminer and intraexaminer reliability of the microperimeter MP-1.

Purpose: To evaluate the interexaminer and intraexaminer reliability of macular microperimetry using the microperimeter MP-1. METHODS PARTICIPANTS: Fifteen healthy volunteers younger than 40 years of age (Group 1), 15 healthy subjects over 60 years (Group 2), and five patients with age-related macular degeneration (Group 3).

Observation Procedure: Two examiners (E1 and E2) measured, in random order, interexaminer (E2-E1a) reliability.

Reduced fluence versus standard photodynamic therapy in combination with intravitreal triamcinolone: short-term results of a randomised study.

Background: To compare early treatment effect of reduced fluence versus standard photodynamic therapy (rPDT, sPDT, respectively) in combination with intravitreal triamcinolone (IVTA) in neovascular age-related macular degeneration.

Methods: Forty patients received either sPDT (group A, n = 20) or rPDT (group B, n = 20) each followed by same-day 4 mg IVTA. Patients were examined at baseline, day 1, week 1, 4 and 12.

Changes in retinal sensitivity in patients with neovascular age-related macular degeneration after systemic bevacizumab (avastin) therapy.

Objective: To evaluate changes in central retinal sensitivity in patients with neovascular age-related macular degeneration after systemic bevacizumab (Avastin; Genentech, Inc., South San Francisco, CA) therapy.

Methods: For all eyes, the central 12 x 12 degrees visual field was recorded using the MP 1 Microperimeter (Nidek, Gamagori, Japan) at baseline and 1 week, 1 month, 3 months, and 6 months after initial treatment.

[Three-dimensional imaging in central serous chorioretinopathy].

Background: Conventional optical coherence tomography (OCT) has brought new insights to retinal diagnostics, but it is restricted due to its low scanning speed and limited resolution. In this study, high-resolution raster scanning OCT (HR-OCT) was used to identify typical changes in central serous chorioretinopathy (CSC).

Methods: Fifteen consecutive patients with acute CSC were imaged using HR-OCT with an axial image resolution of 6 mum.

[Three-dimensional optical coherence tomography for evaluating the retinal architecture before and after surgery for vitreomacular traction.].

PURPOSE: To investigate the morphology of the vitreoretinal interface before and after delamination of epiretinal membranes using three-dimensional volumetric high-resolution optical coherence tomography (HROCT). METHODS: Extension and intensity of vitreomacular traction due to epiretinal membranes (ERM) and the architecture of retinal layers in 14 eyes of 14 patients were evaluated preoperatively using high-resolution raster scanning OCT (Cirrus prototype, resulting in a 6x6-mm field, 2 mm in depth). Additionally, stratus OCT, visual acuity testing, and fundus photography were performed.

[High-resolution optical coherence tomography to evaluate vitreomacular traction before and after membrane peeling].

Aim: Morphological assessment of the vitreomacular interface and intraretinal architecture using three-dimensional high-resolution optical coherence tomography (HROCT) before and after surgical delamination of epiretinal membranes and the internal limiting membrane (ILM).

Method: The extent and intensity of traction of the epiretinal membrane (ERM) and the morphology of the individual retinal layers were investigated preoperatively in 14 eyes of 14 patients using three-dimensional HROCT (Cirrus prototype, scanned area 6x6 mm, depth 2 mm). In addition, visual acuity and ophthalmological findings (including stratus OCT) were documented.

Intravitreal bevacizumab (Avastin) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age-related macular degeneration: 6-month results of a prospective, randomised, controlled clinical study.

Aims: To compare functional and anatomical outcomes of intravitreal bevacizumab (Avastin) and verteporfin (photodynamic) therapy (PDT) combined with intravitreal triamcinolone (IVTA) in patients with neovascular age-related macular degeneration (AMD).

Methods: Twenty-eight patients with neovascular AMD were enrolled in a prospective, randomised, controlled clinical trial. All patients randomly assigned to 1 mg intravitreal bevacizumab (0.

[The role of Stratus OCT in anti-VEGF therapy. Qualitative and quantitative assessment of neovascular AMD].

Background: The evaluation of OCT3 during anti-VEGF therapy.

Methods: A total of 29 patients with choroidal neovascularization secondary to AMD received 3 intravitreal injections of ranibizumab. OCT examination and visual acuity testing (ETDRS) were performed before therapy onset, after 1 week and after 1, 2 and 3 months.

Value of polarisation-sensitive optical coherence tomography in diseases affecting the retinal pigment epithelium.

Objectives: To evaluate pathological changes of retinal pigment epithelium (RPE) by polarisation-sensitive optical coherence tomography (PS-OCT).

Methods: Forty-four eyes (22 patients) with significant pathologies of the RPE were evaluated using PS-OCT. A transversal scanning time domain OCT system was used for two-dimensional cross-sectional imaging of retinal polarisation properties.

Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study.

Objective: To evaluate efficacy and safety of intravitreal bevacizumab (Avastin) in eyes with macular oedema secondary to central retinal vein occlusion (CRVO) or branch retinal vein occlusion (BRVO).

Methods: Twenty-eight consecutive patients (28 patients, 29 eyes, 8 CRVO, 21 BRVO) were enrolled in the study. Three intravitreal injections of 1 mg bevacizumab (0.

Rapid improvement of radiation-induced neovascular glaucoma and exudative retinal detachment after a single intravitreal ranibizumab injection.

Neovascular glaucoma is a serious complication arising from irradiation of uveal melanoma. Treatment options include panretinal photocoagulation, peripheral retina cryotherapy, photodynamic therapy with verteporfin, triamcinolone injections and surgical removal of the dying tumour mass. Nevertheless, enucleation of the affected eye often is inevitable.

Ultrastructural changes in a murine model of graded Bruch membrane lipoidal degeneration and corresponding VEGF164 detection.

Purpose: To evaluate ultrastructural changes in low-density lipoprotein (LDL) receptor knockout (R(-/-)) mice consuming different diets as a potential model of Bruch membrane (BM) lipoidal degeneration and to determine the distribution and concentration of VEGF(164) in this mouse model.

Methods: Eight-month-old LDL-R(-/-) mice and wild-type controls were fed a standard or a high-fat diet. Animals were killed, and plasma cholesterol levels were determined.

Randomized multicenter trial of more intense and standard early verteporfin treatment of neovascular age-related macular degeneration.

Purpose: To compare efficacy and safety of a more intense regimen versus a standard one for retreatment of neovascular age-related macular degeneration (AMD) during the early period of verteporfin therapy (VT).

Design: Prospective, randomized, multicenter clinical trial.

Participants: Two hundred three patients with predominantly classic choroidal neovascularization (CNV) secondary to AMD.

Effect of posterior capsule opacification on macular sensitivity.

Purpose: To evaluate the effect of posterior capsule opacification (PCO) on macular sensitivity.

Setting: Department of Ophthalmology, Medical University of Vienna, Vienna, Austria.

Methods: Macular sensitivity, best corrected visual acuity (BCVA), and PCO intensity were evaluated before and after neodymium:YAG (Nd:YAG) laser capsulotomy in pseudophakic eyes with clinically significant PCO that had a healthy macula or dry age-related macular degeneration (ARMD).

Automatic segmentation in three-dimensional analysis of fibrovascular pigmentepithelial detachment using high-definition optical coherence tomography.

Background/aims: A limited number of scans compromise conventional optical coherence tomography (OCT) to track chorioretinal disease in its full extension. Failures in edge-detection algorithms falsify the results of retinal mapping even further. High-definition-OCT (HD-OCT) is based on raster scanning and was used to visualise the localisation and volume of intra- and sub-pigment-epithelial (RPE) changes in fibrovascular pigment epithelial detachments (fPED).

Intravitreal bevacizumab therapy for neovascular age-related macular degeneration with large submacular hemorrhage.

Purpose: To evaluate functional and anatomic effects of intravitreal bevacizumab (Avastin; Roche Pharma, Vienna, Austria) in patients with neovascular age-related macular degeneration (AMD) with large submacular hemorrhages.

Design: Retrospective, clinical study.

Methods: Twenty-one eyes of 19 AMD patients with choroidal neovascularization and large submacular hemorrhage involving the fovea comprising more than 50% of the total lesion area were evaluated.

[New perspectives in diagnostic. High-resolution optical coherence tomography for age-related macular degeneration].

Background: Recent advances in optical coherence tomography (OCT) have made it possible to increase resolution and scan velocities so that even greater central areas of the retina can be scanned. The aim of this study is to describe the possibilities offered by this new technology for age-related macular degeneration.

Material And Methods: The study included 20 patients with confirmed active choroidal neovascularization (CNV) as well as pigment epithelial detachment (PED).

Guidance for the treatment of neovascular age-related macular degeneration.

Neovascular age-related macular degeneration is becoming an increasing socio-medical problem as the proportion of the aged population is continuously increasing. However, new insights in the pathogenesis of the disease offer the opportunity to develop targeted therapies that attack the disease process more successfully than ever. This review article will focus on summarizing the actual options in the management of neovascular age-related macular degeneration and provide a short overview about recent therapeutic options in clinical and preclinical evaluation.

Central visual field impairment during and following cystoid macular oedema.

Aim: To determine differential light threshold values obtained with the Micro Perimeter 1 (MP1) in uveitis patients suffering from cystoid macular oedema (CMO) and to compare these measures to retinal thickness.

Methods: Static threshold perimetry was performed with the MP1 Microperimeter in 27 eyes of 21 patients with a history of chronically recurring CMO. Active CMO was confirmed in 19 eyes.

[Intravitreal bevacizumab versus verteporfin and intravitreal triamcinolone acetonide in patients with neovascular age-related macula degeneration].

Aim: The aim of this study was to compare intravitreal bevacizumab (IVB) and verteporfin therapy in combination with 4 mg intravitreal triamcinolone (PDT-IVTA) in patients with neovascular age-related macular degeneration (AMD).

Patients And Methods: A total of 30 eyes of 30 patients with neovascular AMD were included in a prospective, randomized study. Ten eyes received PDT-IVTA with a standard light fluence of 50 J/cm(2) (SPDT-IVTA), ten were treated with PDT-IVTA with a reduced light fluence of 25 J/cm(2) (RPDT-IVTA) and ten received IVB.

Management of neovascular age-related macular degeneration.

Neovascular age-related macular degeneration (AMD) is becoming an increasing socio-medical problem as the proportion of the aged population is continuously increasing. However, new insights in the pathogenesis of the disease offer the opportunity to develop targeted therapies that attack the disease process more successfully than ever. This review article will focus on summarizing the actual options in the management of neovascular AMD and provide a short overview about recent therapeutic options in clinical and preclinical evaluation.